{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:10:38Z","timestamp":1790359838234,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ymthe.2019.04.001","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T20:41:53Z","timestamp":1554756113000},"page":"1126-1138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"title":["Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma"],"prefix":"10.1016","volume":"27","author":[{"given":"Cesar","family":"Sommer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Boldajipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy C.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Galetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Valton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Juillerat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Gariboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Pascua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherman M.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Duchateau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Rajpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Van Blarcom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Chaparro-Riggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbra J.","family":"Sasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2019.04.001_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fimmu.2013.00107","article-title":"When aging reaches CD4+ T-cells: phenotypic and functional changes","volume":"4","author":"Moro-Garc\u00eda","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2019.04.001_bib4","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1073\/pnas.1714478115","article-title":"Thymic involution and rising disease incidence with age","volume":"115","author":"Palmer","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.04.001_bib5","first-page":"595","article-title":"T cell ageing: effects of age on development, survival & function","volume":"138","author":"Salam","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ymthe.2019.04.001_bib6","doi-asserted-by":"crossref","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T\u00a0cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib7","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.001_bib8","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in expansion potential of naive chimeric antigen receptor T\u00a0cells from healthy donors and untreated chronic lymphocytic leukemia patients","volume":"8","author":"Hoffmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2019.04.001_bib9","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immmunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2019.04.001_bib10","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T\u00a0cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2019.04.001_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.omtn.2017.10.005","article-title":"Fine and predictable tuning of TALEN gene editing targeting for improved T\u00a0cell adoptive immunotherapy","volume":"9","author":"Gautron","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2019.04.001_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long terminal repeat CRISPR-CAR-coupled \u201cuniversal\u201d T\u00a0cells mediate potent anti-leukemic effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.001_bib13","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T\u00a0cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V130.Suppl_1.887.887","article-title":"Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"130","author":"Graham","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.001_bib15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib16","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2019.04.001_bib17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2019.04.001_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib19","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.001_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2019.04.001_bib21","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-07-0464","article-title":"Antibody targeting of B-cell maturation antigen on malignant plasma cells","volume":"6","author":"Ryan","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2019.04.001_bib22","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.molonc.2015.03.010","article-title":"Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma","volume":"9","author":"Oden","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2019.04.001_bib23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in\u00a0vitro and in\u00a0vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2019.04.001_bib24","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2019.04.001_bib25","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.001_bib26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.001_bib27","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","article-title":"CAR T\u00a0cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin\u2019s lymphoma and multiple myeloma","volume":"26","author":"Bluhm","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.001_bib28","doi-asserted-by":"crossref","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T\u00a0cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2019.04.001_bib29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T\u00a0cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2019.04.001_bib30","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T\u00a0cell vector","volume":"26","author":"Smith","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.001_bib31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.001_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T\u00a0cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2019.04.001_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB costimulation in chimeric antigen receptors impedes T\u00a0cell survival and is vector-dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2019.04.001_bib35","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T\u00a0cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2019.04.001_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T\u00a0cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2019.04.001_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1089\/hgtb.2013.022","article-title":"Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T\u00a0cell therapy for cancer","volume":"24","author":"Alcantar-Orozco","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2019.04.001_bib39","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T\u00a0cell-mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.001_bib40","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T\u00a0cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2019.04.001_bib41","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in\u00a0vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.001_bib42","doi-asserted-by":"crossref","first-page":"8972","DOI":"10.1038\/s41598-018-27264-w","article-title":"A versatile safeguard for chimeric antigen receptor T-cell immunotherapies","volume":"8","author":"Valton","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2019.04.001_bib43","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T\u00a0cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T\u00a0cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2019.04.001_bib45","doi-asserted-by":"crossref","first-page":"e4749","DOI":"10.1371\/journal.pone.0004749","article-title":"Fludarabine modulates immune response and extends in\u00a0vivo survival of adoptively transferred CD8 T\u00a0cells in patients with metastatic melanoma","volume":"4","author":"Wallen","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.04.001_bib46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex\u00a0vivo-engineered T\u00a0cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.001_bib47","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2019.04.001_bib48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1634\/theoncologist.2007-0218","article-title":"FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia","volume":"13","author":"Demko","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ymthe.2019.04.001_bib49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jcyt.2013.05.016","article-title":"Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery","volume":"15","author":"G\u00e4rtner","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2019.04.001_bib50","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T\u00a0cells by gamma(c) family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2019.04.001_bib51","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1172\/JCI200523134","article-title":"Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool","volume":"115","author":"Melchionda","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2019.04.001_bib52","doi-asserted-by":"crossref","first-page":"e0166280","DOI":"10.1371\/journal.pone.0166280","article-title":"Interleukins 7 and 15 maintain human T\u00a0cell proliferative capacity through STAT5 signaling","volume":"11","author":"Drake","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.04.001_bib53","doi-asserted-by":"crossref","first-page":"e1002720","DOI":"10.1080\/2162402X.2014.1002720","article-title":"Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review","volume":"4","author":"Nayar","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2019.04.001_bib54","doi-asserted-by":"crossref","first-page":"e88205","DOI":"10.1371\/journal.pone.0088205","article-title":"An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T\u00a0cells in mice","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.04.001_bib55","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T\u00a0cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2019.04.001_bib56","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.4049\/jimmunol.180.11.7265","article-title":"IL-7\/anti-IL-7 mAb complexes restore T\u00a0cell development and induce homeostatic T Cell expansion without lymphopenia","volume":"180","author":"Boyman","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2019.04.001_bib57","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1074\/jbc.M508624200","article-title":"Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta\/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins","volume":"281","author":"Mortier","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2019.04.001_bib58","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1073\/pnas.0600240103","article-title":"Converting IL-15 to a superagonist by binding to soluble IL-15Ralpha","volume":"103","author":"Rubinstein","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.04.001_bib59","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.177.9.6072","article-title":"Combined IL-15\/IL-15Ralpha immunotherapy maximizes IL-15 activity in\u00a0vivo","volume":"177","author":"Stoklasek","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2019.04.001_bib60","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity","volume":"12","author":"van Meerten","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2019.04.001_bib61","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J.\u00a0Clin. Oncol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619301650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619301650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:55:00Z","timestamp":1761501300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001619301650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1525001619301650"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.001","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}